In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant

Diagnostic Microbiology and Infectious Disease

Volumn 60, Issue 2, 2008, Pages 155-161

  Schafer, Jeremy ^a   Hovde, Laurie B ^a   Simonson, Dana ^a   Rotschafer, John C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Binding affinity; DNA gyrase; Topoisomerase IV

Indexed keywords

LEVOFLOXACIN; MOXIFLOXACIN; MUTANT PROTEIN; PROTEIN PARC;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; IN VITRO STUDY; MUTATION; NONHUMAN; PHARMACODYNAMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; WILD TYPE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUTATION; OFLOXACIN; POLYMERASE CHAIN REACTION; QUINOLINES; STREPTOCOCCUS PNEUMONIAE;

EID: 38149141717     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.08.005     Document Type: Article

References (31)

1. Allen G.P., Kaatz G.W., and Rybak M.J. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47 (2003) 2606-2614
2. Ambrose P.G., and Grasela D.M. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 38 (2000) 151-157
3. Bast D.J., Low D.E., Duncan C.L., Kilburn L., Mandell L.A., Davidson R.J., and de Azavedo J.C.S. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44 (2000) 3049-3054
4. Bell J.M., Turnidge J.D., and Jones R.N. Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756. Int. J. Antimicrob. Agents 19 (2002) 125-132
5. Bhavnani S.M., Hammel J.P., Jones R.N., and Ambrose P.G. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn. Microbiol. Infect. Dis. 51 (2005) 31-37
6. Brenwald N.P., Appelbaum P., Davies T., and Gill M.J. Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Clin. Microbiol. Infect. 9 (2003) 140-143
7. Broskey J., Coleman K., McCloskey L., Traini C., and Warren R. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 45 Suppl 1 (2000) 95-99
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement (2006), CLSI, Villanova, PA, Villanova, PA, USA: CLSI
9. Davies T.A., Evangelista A., Pfleger S., Bush K., Sahm D.F., and Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob. Agents Chemother. 46 (2002) 119-124
10. Davies T.A., and Goldschmidt R. Screening of large numbers of Streptococcus pneumoniae isolates for mutations associated with fluoroquinolone resistance using an oligonucleotide probe assay. FEMS Microbiol. Lett. 217 (2002) 219-224
11. Davies T.A., Goldschmidt R., Pfleger S., Loeloff M., Bush K., Sahm D.F., and Evangelista A. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J. Antimicrob. Chemother. 52 (2003) 168-175
12. Florea N.R., Tessier P.R., Zhang C., Nightingale C.H., and Nicolau D.P.. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48 (2004) 1215-1221
13. Goldstein E.J., and Garabedian-Ruffalo S.M. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin. Infect. Dis. 35 (2002) 1505-1511
14. Gordon K.A., Biedenbach D.J., and Jones R.N. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 46 (2003) 285-289
15. Hoban D.J., Doern G.V., Fluit A.C., Roussel-Delvallez M., and Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32 Suppl 2 (2001) S81-S93
16. Ibrahim K.H., Hovde L.B., Ross G., Gunderson B., Wright D.H., and Rotschafer J.C. Microbiologic effectiveness of time- or concentration-based dosing strategies in Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 44 (2002) 265-271
17. Janoir C., Zeller V., Kitzis M.D., Moreau N.J., and Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40 (1996) 2760-2764
18. Jones M.E., Sahm D.F., Martin N., Scheuring S., Heisig P., Thornsberry C., Köhrer K., and Schmitz F.J. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44 (2000) 462-466
19. Jones R.N., and Pfaller M.A. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999). J. Clin. Microbiol. 38 (2000) 4298-4299
20. Jones R.N., Fritsche T.R., and Sader H.S. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 52 (2005) 129-133
21. Karlowsky J.A., Thornsberry C., Critchley I.A., Jones M.E., Evangelista A.T., Noel G.J., and Sahm D.F. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob. Agents Chemother. 47 (2003) 1790-1797
22. Karlowsky J.A., Thornsberry C., Jones M.E., Evangelista A.T., Critchley I.A., Sahm D.F., and TRUST Surveillance Program. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin. Infect. Dis. 36 (2003) 963-970
23. Lim S., Bast D., McGeer A., de Azavedo J., and Low D.E. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg. Infect. Dis. 9 (2003) 833-837
24. Morosini M.I., Loza E., del Campo R., Almaraz F., Baquero F., and Cantón R. Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including stains with altered topoisomerases. Antimicrob. Agents Chemother. 47 (2003) 2692-2695
25. Munoz R., and De La Campa A.G. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40 (1996) 2252-2257
26. Pestova E., Millichap J.J., Noskin G.A., and Peterson L.R. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother. 45 (2000) 583-590
27. Piddock L.J., Johnson M.M., Simjee S., and Pumbwe L. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46 (2002) 808-812
28. Thornsberry C., Sahm D.F., Kelly L.J., Critchley I.A., Jones M.E., Evangelista A.T., and Karlowsky J.A. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin. Infect. Dis. 34 Suppl 1 (2002) S4-S16
29. Urban C., Rachman N., Zhao X., Mariano N., Segal-Maurer S., Drlica K., and Rahal J.J. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J. Infect. Dis. 184 (2001) 794-798
30. Wright D.H., Herman V.K., Konstantinides F.N., and Rotschafer J.C. Determination of quinolone antibiotics in growth media by reversed-phase high-performance liquid chromatography. J. Chromatogr. B. Biomed. Sci. Appl. 709 (1998) 97-104
31. Zelenitsky S.A., Ariano R.E., Iacovides H., Sun SiYao, and Harding G.K.M. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J. Antimicrob. Chemother. 51 (2003) 905-911